From The Mobile Desk of VacationRespert24 Location:

New Post Public Reply Private Reply Replies (2) Message Board
Respert24
895
From The Mobile Desk of VacationRespert24
Location: Secret
5/19/2021
8:01am

As many as four of you may have been wondering where I've been. Wondering whether or not I have anything to say about the FDA going out of their way to shit on CYDY, during trading hours no less. Maybe even wondering whether the beef shortage caused by the coronavirus has led to dangerously low iron levels in your hero, leaving me too weak to post regularly.

Res(per)t assured that my steak consumption is at an all time high, including a ribeye topped with a bacon relish just last night. A bottle of J Lohr Pure Paso followed by a bottle of Jordan Cabernet washed it down. I wasn't alone, so don't call an intervention just yet. And if need be I'll switch to hippo. Seriously. Google "meat shortage hippo" for an interesting read on the subject.

And I have been trying to keep up with the fireworks even though the "show" has basically felt we bought the world's best fireworks kit and later found out it was just a box with a couple sacks of flour taped inside for weight.

But like those stories you occasionally hear about where a man decides to put a new frame on the weird painting he found at a garage sale for $1 and finds a Renoir underneath, those bags of white powder actually contain a substance far more explosive than big fireworks wants you to believe. That raw, uncut LL is going to rattle the world.

Like many of you, I watched a fairly massive amount of money disappear from my spreadsheet. This happened right after I did two things, in case you want to feel like it isn't just you getting jabbed in the eye with a hot poker.

First, my upstairs HVAC bit the dust. Along with the new system, we're redoing the shoddy ductwork upstairs as well as the ductwork on our other system downstairs. Rerouting, adding returns, widening vents. The whole shebang. This crappy news was preceded by my decision to take the family on a little trip. Nothing crazy, just a couple nights a short drive away, but between the two I quickly ended up down 15k before the FDA letter even came out. So it's been twice as annoying for me the last few days. The only lucky moment was when I sold a small bit of my holdings to help fund these two projects at $2.74, right before the drop. Then again, if I was truly lucky this would have happened back when it was bouncing around $6.

Like many of you I'm frustrated with the FDA. What kind of asshole authorizes that in the first place without paying attention to facts? And what kind of supreme asshole then decides to release it DURING trading hours? I hope some savvy investor is able to out whoever it was that penned it and/or chose to release it the way they did. There deserves to be some public shaming of that person or team. Which coincidentally is probably why the did it in the first place. Lots of people calling them out on their bullshit.

But does the letter change anything?

I don't think any sane investor thought we were realistically going to get an EUA here in the states without more data. Which means many other countries likely won't or wouldn't budge without more data. It sucks, because by all accounts we should be the perfect choice for an EUA, but you can't teach an old dog new tricks and the FDA isn't going to change their glacially paced, archaic process for little old Cytodyn. They'll get the data they need and it'll be fine. That's what Brazil is for. That's what a proper trial design will provide. There'll be irrefutable proof that the FDA can finally except. At which point the mood will switch from the entitled asshole looking down at LL into the smiling and inviting host, who immediately pulls out all the stops because they realize they've stumbled upon a whale. Right this way, Mr. Papagiorgio. Your penthouse suite is ready.

As sure as I'll continue to eat two filets whenever I'm on the road for work, Leronlimab will continue to prove itself in trials, EINDs, OLEs, CSPs, cancer, Longhaulers, HIV, GVD, and probably 64 other acronym-heavy conditions from Ohm20's list. The science is strong and the future is bright. Nobody ever said it would be easy.

Lastly, here's a good post from "Money Made Money Kept" on the yahoo board:

I've been wanting to add my perspective as a long-time regulatory professional after seeing the statement from FDA yesterday, hearing doom and gloom summaries of the CC from various naysayers, and then listening to the CC myself. TLR summary = I thought the call went very well given the circumstances, and things still seem to be on track.

First and foremost I was impressed with the unified, conciliatory and friendly tone of CYDY management towards FDA, which must have been a challenging position to take after the events of yesterday. This means they are clearly focused on moving forward with US FDA, and that they are not willing to indulge in conspiracy theories of BP/FDA corruption and other distractions which (whether true or not) are just that - distractions. If Nader and CYDY management ever decide to start indulging such distractions and stop focusing on making forward progress, I will promptly sell all of my shares.

The tone and content of the FDA statement from yesterday was consistent with many I have read before in confidential correspondence with them. The only reason I can think that it was published on FDA's website is that they must have been facing overwhelming public advocacy for Leronlimab, and clearly some of it (probably a lot of it) was from people who are misinformed. Some of this can be fairly blamed on the hyperbole of CYDY executive management, which I've unfortunately found to be ubiquitous among small biotech C-suites; however, some blame must also go to FDA, who has made a number of high-profile blunders and questionable approvals throughout this pandemic. Regardless, over the years I have regularly had to reassure stakeholders that FDA is simply incredibly risk-averse, and their written correspondence should not be taken personally. It is unfortunate that their statement was made publicly available to shareholders at large, who have clearly over-reacted given that no new information was shared with us.

Finally, the clarity Nader provided on their move overseas makes perfect sense in the context of drug development: if you live in a country where there are no patients in your intended treatment population (i.e. severe COVID), you must go overseas to enroll patients. It had nothing to do with FDA asserting that there was no path forward for Leronlimab. This was a straightforward and sensible answer to my main question of what precipitated the move overseas, and whether it had to do with bad blood here in the US.

In sum: I'm not surprised by the FDA letter, although I feel its publication was unfair to CYDY shareholders. However, life is often unfair, and companies must not be distracted by fairness if they are to succeed (the same is true for investors). CYDY seems focused on keeping their heads down and generating the data that is needed to move forward, and contrary to what STAT news keeps insisting, the totality of available data supports the conclusion that CCR5 is an important therapeutic target in multiple indications. I can't guarantee that CYDY will succeed against the many headwinds that small biotech companies face, nor am I thrilled about the slow pace of progress and occasional setbacks, but I continue to hold my shares because I don't feel that the thesis has changed. An approval of some type (EUA, BLA, etc) still seems likely for CYDY in the near future.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 70

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 66

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 118

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 144

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Allstate's October Cat Loss Lands at $232 Million Net

Updated Category News Views 75

October’s weather bill arrived without much poetry: $232 million in estimated catastrophe losses at Allstate. Reported on November 19, that figure falls to $184 million after tax, and it deserves a clear-eyed read rather than the usual insurance-stock theatrics. A single monthly catastrophe tally is not a verdict on the company, but it is absolutely part of the...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 36

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading

Top 5 Most Recently Viewed Articles

Priority Plumbing & Heating Expands with New Boiler Services

Updated Category News Views 215

Priority Plumbing & Heating Expands to Meet Growing Demand Priority Plumbing & Heating, a notable provider of home services, is delighted to announce the expansion of its offerings to include specialized boiler repair and installation services. This strategic move aims to meet the increasing demand for advanced heating systems among homeowners and businesses situated...

Continue Reading
TGS Secures Major 4D Streamer Contracts in Norway

Updated Category News Views 314

Major Contracts Awarded to TGS for 4D Streamer Campaign TGS, a leading provider of energy data and intelligence, has exciting news to share regarding its latest venture in offshore operations. The company has successfully secured contracts for four 4D streamer acquisition projects, marking a significant step forward in their commitment to provide high-quality energy data....

Continue Reading
Stanley Black & Decker: Solid Growth Amidst Challenges

Updated Category News Views 102

Stanley Black & Decker's Growth Initiatives Stanley Black & Decker, Inc. (NYSE: SWK) is currently executing an aggressive cost-reduction program aimed at enhancing its financial performance. This plan involves resizing the organization, streamlining inventory, and optimizing the supply chain. The overarching goal is to reshape the company for sustainable growth in the...

Continue Reading
Armada Partners with US Department of Energy on Genesis Mission

Updated Category News Views 185

Armada's Collaboration with the US Department of Energy Armada has announced a significant collaboration with the U.S. Department of Energy (DOE) related to the Genesis Mission. This ambitious initiative aims to modernize the approach to scientific research across the country. The Genesis Mission seeks to integrate various technological resources and national laboratories...

Continue Reading
Exploring MercadoLibre's Recent Options Activity Trends

Updated Category News Views 200

Understanding Recent Options Trends for MercadoLibre In the intriguing world of options trading, a substantial number of investors are signaling optimism about MercadoLibre (MELI). Recent activities indicate a notable bullish sentiment that retail traders should definitely pay attention to. Today's market data reveals an extraordinary series of trades, sparking curiosity...

Continue Reading